Two Sigma Advisers’s Summit Therapeutics SMMT Stock Holding History

Two Sigma Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,700	Closed	-$187K	–	1825
2025 Q4	$187K	Buy	+10,700	New	+$201K	﹤0.01%	2137

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Advisers's SMMT Position: Q1 2026 in Review

Two Sigma Advisers sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 10,700 shares — an estimated $187K sold.

Two Sigma Advisers first reported a position in SMMT in Q4 2025 and held it in 1 quarter. The position peaked at $187K in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Two Sigma Advisers reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 10,700 Summit Therapeutics shares in Q1 2026, an estimated $187K.
Two Sigma Advisers first reported a position in Summit Therapeutics in Q4 2025 and held it in 1 quarter.
Two Sigma Advisers's Summit Therapeutics position peaked at $187K in Q4 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.